



16 February 2012
EMA/CHMP/539928/2010

Application form

For a post-consultation procedure on an ancillary medicinal substance in a medical device

European Medicines Agency (EMA) procedure number¹: EMEA/H/D/<Number>

Type of application (tick all applicable options)

- Minor amendment (equivalent to Type IA)
- Minor amendment (equivalent to Type IB)
- Major amendment (equivalent to Type II)

Changes concern (for Type IB and Type II variations only, tick all changes applicable)

- Quality
- Non-clinical
- Clinical
- Other

Name and address of the applicant (notified body): <Name> <Address> <Postcode> <City> <Country>	Name and address of contact person ² : <Name> <Address> <Postcode> <City> <Country> Telephone number: <Number> Fax number (optimal): <Number> E-mail: <E-mail address>
-------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

¹ The sequential EMA procedure number (not the applicant's internal number) should be provided here, when known to the applicant.

² If different from the authorised contact point, please provide a letter of authorisation.



Medical device(s) concerned by this application³

EMA number	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Packaging	Content (concentration)	Package size
<EMA product number { EMEA/H/D/0000/00/00/00} >	<Name>						

Or,

EMA number	(Invented) Name	Strength
<EMA product number { EMEA/H/D/0000/00/00/00} >	<Name>	

³ If this list is very extensive (more than one page) it may be added as annex to the application form. The format to be used should be the same as Annex I of the initial consultation procedure.

Changes included in this application

The changes included in this application are classified as:

Changes in an ancillary medicinal substance incorporated in a medical device (post-consultation procedure)			Procedure type
<input type="checkbox"/>	a)	Minor change (equivalent to type IA)	IA
<input type="checkbox"/>	b)	Minor change (equivalent to type IB)	IB
<input type="checkbox"/>	c)	Major change (equivalent to type II)	II

The post-consultation procedures on an ancillary medicinal substance in a medical device are classified as minor/major amendments by analogy to [Commission Regulation \(EC\) 1234/2008](#) and the [Commission Classification Guideline for variations on marketing authorisation for medicinal products](#).

By analogy, the proposed changes could be classified as:

Variation number*	Procedure type
	<input type="checkbox"/> IA <input type="checkbox"/> IB <input type="checkbox"/> II

* According to the classification guideline.

Precise scope and background of the changes⁴:

<Text>

Present ⁵	Proposed ⁵
<Text>	<Text>

Other applications under revision (if applicable):

<Text>

Documentation provided⁶:

<Text>

⁴ Include a description and background of all proposed changes.

⁵ Specify the precise present and proposed wording or specification, including dossier section number(s) at the lowest possible level.

⁶ Include a description of all the documentation provided.

Declaration of the applicant

I hereby submit a notification/application for the above consultation procedure(s) to be varied in accordance with the proposals given above. I declare that (*please tick the appropriate declarations*):

There are no other changes than those identified in this application (except for those addressed in other variations submitted in parallel).

The changes do not adversely affect the usefulness of the ancillary medicinal substance as part of the medical device as initially verified by the notified body.

Where applicable, all conditions as set for the variation(s) concerned are fulfilled.

For type IA notifications: the required documents as specified for the changes concerned in analogy to [Commission Classification Guideline for variations on marketing authorisation for medicinal products](#) have been submitted.

Where applicable, fees have been paid.

Changes will be implemented from⁷: Next production run/next printing.

Date: <DD Month YYYY>.

<p>Main signatory⁸:</p> <p>_____</p> <p>Print name: <Name></p>	<p>Status (job title): <Job title></p> <p>Date: <DD Month YYYY></p>
<p>Second signatory:</p> <p>_____</p> <p>Print name: <Name></p>	<p>Status (job title): <Job title></p> <p>Date: <DD Month YYYY></p>

⁷ Only to be completed for type IB and type II variations.

⁸ The signature of the main signatory is mandatory.